Tasly Pharma Trials Qishen Yiqi Pills for Chronic Heart Failure
Tasly Pharmaceutical is conducting a trial to assess the efficacy and safety of Qishen Yiqi Dripping Pills for chronic heart failure with reduced ejection fraction.
Phase III
Cardiology / Heart Failure
Status
Active
Sponsor
Tasly Pharmaceutical
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing trial of Qishen Yiqi Dripping Pills by Tasly Pharma represents a significant opportunity to introduce a novel treatment in the chronic heart failure space. Success could not only enhance Tasly's portfolio but also disrupt the current competitive landscape in cardiology.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and any subsequent regulatory filings or partnerships that may arise from the findings.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.